ART with long-term effects without immunosuppression

Published Date: 02 Mar 2023

The latest studies of long-acting ART show benefits even in people who are not immune. Meanwhile, early proof-of-concept results for twice-yearly injection are encouraging.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.

2.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

3.

Next Day Mood Is Affected by Ability to Recover From Work.

4.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

5.

Review looks at potential treatment targets in the tumor microenvironment.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot